Forskolin is a well-known compound that directly stimulates adenylyl cyclase, thereby increasing intracellular cyclic AMP (cAMP) levels. The elevation of cAMP activates protein kinase A (PKA), which then goes on to phosphorylate specific proteins, possibly including CDRT15L2, leading to their activation. Similarly, IBMX functions to elevate cAMP levels by inhibiting phosphodiesterases, which break down cAMP. As a result, IBMX contributes to the prolonged activation of PKA, creating a conducive environment for the phosphorylation and consequent activation of proteins akin to CDRT15L2. Phorbol 12-myristate 13-acetate (PMA) is another activator that directly engages with protein kinase C (PKC), a family of kinases that phosphorylate a broad range of target proteins, which could include CDRT15L2. This phosphorylation is a critical step in the activation of many proteins within the cell. On a different front, LY294002 works by inhibiting phosphoinositide 3-kinases (PI3K), which in turn affects the AKT signaling pathway. This can lead to changes in the phosphorylation status of various proteins within the cell, potentially causing the activation of CDRT15L2.
The MEK inhibitors PD98059 and U0126, by altering the MAPK/ERK pathway, could also change the phosphorylation pattern of proteins, leading to the activation of CDRT15L2. Inhibitors like SB203580 and SP600125, which target p38 MAPK and JNK respectively, modulate these kinases' pathways, affecting the phosphorylation and activity of a range of proteins, potentially including CDRT15L2. KN-93 is known to inhibit CaMKII, a kinase responsive to calcium levels, which plays a significant role in phosphorylating proteins and regulating their activity. Okadaic Acid, a potent inhibitor of protein phosphatases PP1 and PP2A, ensures that proteins within the cell remain phosphorylated, which could lead to the activation of CDRT15L2. Anisomycin disrupts protein synthesis but also activates stress-activated protein kinases, which could indirectly lead to the phosphorylation and activation of CDRT15L2.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Activates adenylyl cyclase, increasing cAMP levels and subsequently activating PKA, which can phosphorylate target proteins including CDRT15L2. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Non-specific phosphodiesterase inhibitor, raising cAMP levels in cells, thereby sustaining the activation of PKA and enhancing the phosphorylation of proteins such as CDRT15L2. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Direct activator of PKC which can lead to the phosphorylation and subsequent activation of proteins including CDRT15L2. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Increases intracellular calcium levels, which can activate calcium-dependent kinases that may phosphorylate and activate CDRT15L2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, affecting AKT signaling and leading to alterations in the phosphorylation state of proteins, which includes potential activation of CDRT15L2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor, which alters the MAPK/ERK pathway and can change the phosphorylation pattern of various proteins, potentially including CDRT15L2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Also a MEK inhibitor, altering the MAPK/ERK signaling and potentially leading to changes in CDRT15L2 activity through modified phosphorylation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAPK, altering the phosphorylation state of downstream proteins and can lead to the activation of CDRT15L2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
JNK inhibitor, which can modulate JNK pathway signaling and affect the activity of proteins including CDRT15L2 through altered phosphorylation states. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
Inhibits CaMKII, a calcium/calmodulin-dependent protein kinase, which can lead to changes in the phosphorylation and activity of various proteins, including CDRT15L2. |